Erenumab cost-effective option for migraine prevention in Portugal
- PDF / 169,870 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 90 Downloads / 206 Views
1
Erenumab cost-effective option for migraine prevention in Portugal Erenumab is a cost-effective option for the prevention of migraine in patients in Portugal who did not respond to prior preventive treatment, according to a study presented at the Virtual 23rd Annual European Congress of the International Society for PharmacoEconomics and Outcomes Research (ISPOR), held 16–19 November 2020.1 The study used an economic model to compare the lifetime health benefits and costs of erenumab with those of placebo for the prevention of migraine in adults with ≥ 3 prior preventive treatment failures. The analyses were performed from both societal and NHS perspectives in Portugal. From a societal perspective, the model showed that erenumab was associated with a gain of 0.28 discounted (0.60 undiscounted) quality-adjusted life-years (QALYs) and a total of 255 discounted (678 undiscounted) migraine days avoided, compared with placebo, over a lifetime horizon at lower direct and indirect costs. From an NHS perspective, erenumab was cost effective, with a cost per QALY gained well below the €20 000 threshold. Another study, also presented at the ISPOR Congress, showed that a calculator tool can be used to estimate the burden of migraine in Portugal.2 The tool can be employed to assess the impact of erenumab on direct and indirect costs. The tool can also be used to estimate the number of patients with migraine with prior preventive treatment failures followed by neurologists at NHS hospital in Portugal. The potential impact of erenumab on hospital performance indicators for various scenarios can also be assessed. 1. Silva C, et al. Cost-Effectiveness of Erenumab for the Prevention of Migraine in Portugal. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND56, 16 Nov 2020. 2. Silva C, et al. Calculator Tool to Estimate the Economic Burden of Migraine and IMPACT Scenarios of Erenumab in the NHS Portuguese Hospitals. 23rd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PND48, 16 Nov 2020. 803519774
1173-5503/20/0868-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
PharmacoEconomics & Outcomes News 12 Dec 2020 No. 868
Data Loading...
